VolitionRX (NYSEAMERICAN:VNRX) Given Buy Rating at Maxim Group

VolitionRX (NYSEAMERICAN:VNRX)‘s stock had its “buy” rating restated by equities research analysts at Maxim Group in a research note issued on Thursday,Benzinga reports. They currently have a $4.00 price target on the medical research company’s stock. Maxim Group’s target price would suggest a potential upside of 179.13% from the stock’s current price.

Several other research analysts have also recently commented on the stock. HC Wainwright decreased their target price on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a research note on Monday, April 20th. Benchmark reissued a “hold” rating on shares of VolitionRX in a research note on Tuesday, June 2nd. Finally, Citigroup downgraded shares of VolitionRX to a “hold” rating in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, VolitionRX currently has an average rating of “Hold” and a consensus target price of $28.00.

VolitionRX Stock Performance

Shares of NYSEAMERICAN:VNRX traded up $0.06 on Thursday, hitting $1.43. The company’s stock had a trading volume of 222,566 shares, compared to its average volume of 429,085. VolitionRX has a 12 month low of $1.30 and a 12 month high of $18.80. The stock’s 50-day moving average is $2.53 and its two-hundred day moving average is $4.07. The company has a market capitalization of $12.37 million, a price-to-earnings ratio of -0.34 and a beta of 1.04.

VolitionRX (NYSEAMERICAN:VNRX) last issued its quarterly earnings results on Thursday, May 14th. The medical research company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.27). The firm had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.52 million. Equities analysts expect that VolitionRX will post -2.4 earnings per share for the current fiscal year.

Institutional Trading of VolitionRX

Large investors have recently made changes to their positions in the stock. Armistice Capital LLC lifted its holdings in VolitionRX by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after purchasing an additional 887,351 shares during the last quarter. Lagoda Investment Management L.P. lifted its stake in VolitionRX by 6.7% during the third quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock worth $8,476,000 after purchasing an additional 782,000 shares during the period. Citadel Advisors LLC boosted its stake in shares of VolitionRX by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after purchasing an additional 135,775 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in VolitionRX during the 4th quarter valued at $34,000. Finally, Jane Street Group LLC bought a new position in shares of VolitionRX in the fourth quarter worth about $28,000. Institutional investors own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.